Evidence map›Paper›PMID 36873499›Full record

ArticleHeliyon2023

The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies.

Maryam Shafaati, Kowsar Bagherzadeh, Majid Lotfinia, Hesam Karimi, Ali Teimoori, Mehdi Razazian, Sepideh Meidaninikjeh, Hamed Hosseini, Hamid Reza Jamshidi, Hasan Jalili and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 3 countries.

Maryam ShafaatiDepartment of Microbiology, Faculty Science, Jahrom Branch, Islamic Azad University, Jahrom, Iran.
Kowsar BagherzadehEye Research Center, The Five Senses Health Institute, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran.
Majid LotfiniaPhysiology Research Center, Kashan University of Medical Sciences, Kashan, Iran.
Hesam KarimiDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Ali TeimooriDepartment of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Mehdi RazazianUniversite Paris Saclay, INSERM U1193, AP-HP, Hôpital Paul Brousse, Virology Department, France.
Sepideh MeidaninikjehDepartment of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran.
Hamed HosseiniCenter for Research and Training in Skin Disease and Leprosy, Tehran University of Medical Sciences, Tehran, Iran.
Hamid Reza JamshidiDepartment of Pharmacology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hasan JaliliDepartment of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.
Asghar AbdoliDepartment of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
Pasteur Institute of Iran · IRAlzahra University · IRHamedan University of Medical Sciences · IRIran University of Medical Sciences · IRIslamic Azad University, Jahrom Branch · IRJohannes Kepler University of Linz · ATKashan University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRTehran University of Medical Sciences · IRUniversity of Tehran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over time, the antigenic evolution of emerging variants of SARS-CoV-2 has demanded the development of potential protective vaccines. Administration of additional doses of current vaccines based on the WT spike protein may boost immunity, but their effectiveness has dwindled for patients with more recent variants. Here, we studied the neutralization activity of post-WT strain-based vaccination and a structural simulation

Indexed as

Molecular dynamic simulationsNeutralizing antibodySARS-CoV-2VaccineVariants of concern

Identifiers

PMID36873499
PMCPMC9968494
OpenAlexW4322154688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.